15 research outputs found

    Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo

    Get PDF
    Fibroblast growth factors 19 (FGF19) and 21 (FGF21) have emerged as key regulators of energy metabolism. Several studies have been conducted to understand the mechanism of FGF19 and FGF21 action, however, the data presented has often been inconsistent and at times contradictory. Here in a single study we compare the mechanisms mediating FGF19/FGF21 actions, and how similarities/differences in actions at the cellular level between these two factors translate to common/divergent physiological outputs. Firstly, we show that in cell culture FGF19/FGF21 are very similar, however, key differences are still observed differentiating the two. In vitro we found that both FGF's activate FGFRs in the context of βKlotho (KLB) expression. Furthermore, both factors alter ERK phosphorylation and glucose uptake with comparable potency. Combination treatment of cells with both factors did not have additive effects and treatment with a competitive inhibitor, the FGF21 delta N17 mutant, also blocked FGF19's effects, suggestive of a shared receptor activation mechanism. The key differences between FGF21/FGF19 were noted at the receptor interaction level, specifically the unique ability of FGF19 to bind/signal directly via FGFR4. To determine if differential effects on energy homeostasis and hepatic mitogenicity exist we treated DIO and ob/ob mice with FGF19/FGF21. We find comparable efficacy of the two proteins to correct body weight and serum glucose in both DIO and ob/ob mice. Nevertheless, FGF21 and FGF19 had distinctly different effects on proliferation in the liver. Interestingly, in vivo blockade of FGF21 signaling in mice using ΔN17 caused profound changes in glycemia indicative of the critical role KLB and FGF21 play in the regulation of glucose homeostasis. Overall, our data demonstrate that while subtle differences exist in vitro the metabolic effects in vivo of FGF19/FGF21 are indistinguishable, supporting a shared mechanism of action for these two hormones in the regulation of energy balance

    Dual Beneficial Effects of (-)-Epigallocatechin-3-Gallate on Levodopa Methylation and Hippocampal Neurodegeneration: In Vitro and In Vivo Studies

    Get PDF
    A combination of levodopa (L-DOPA) and carbidopa is the most commonly-used treatment for symptom management in Parkinson's disease. Studies have shown that concomitant use of a COMT inhibitor is highly beneficial in controlling the wearing-off phenomenon by improving L-DOPA bioavailability as well as brain entry. The present study sought to determine whether (-)-epigallocatechin-3-gallate (EGCG), a common tea polyphenol, can serve as a naturally-occurring COMT inhibitor that also possesses neuroprotective actions.Using both in vitro and in vivo models, we investigated the modulating effects of EGCG on L-DOPA methylation as well as on chemically induced oxidative neuronal damage and degeneration. EGCG strongly inhibited human liver COMT-mediated O-methylation of L-DOPA in a concentration-dependent manner in vitro, with an average IC50 of 0.36 microM. Oral administration of EGCG moderately lowered the accumulation of 3-O-methyldopa in the plasma and striatum of rats treated with L-DOPA+carbidopa. In addition, EGCG also reduced glutamate-induced oxidative cytotoxicity in cultured HT22 mouse hippocampal neuronal cells through inactivation of the nuclear factor kappaB-signaling pathway. Under in vivo conditions, administration of EGCG exerted a strong protective effect against kainic acid-induced oxidative neuronal death in the hippocampus of rats.These observations suggest that oral administration of EGCG may have significant beneficial effects in Parkinson's patients treated with L-DOPA and carbidopa by exerting a modest inhibition of L-DOPA methylation plus a strong neuroprotection against oxidative damage and degeneration

    Βιβλιοκρισίαι: Χρυσοστόμου Παπαδοπούλου, Αρχιεπισκόπου Αθηνών και πάσης Ελλάδος. Συμβολαί εις την ιστορίαν του μοναχικού βίου εν Ελλάδι: A’. Ο όσιος Λουκάς “ο νέος” (396-955), Β'. Ο όσιος Μελέτιος “ο νέος” (1035-1195), Αθήναι, 1935

    No full text
    <p>Administration of recombinant FGF19 or FGF21 led to a reduction in body mass in a dose dependent fashion (A). Both FGF19 and FGF21 therapy led to a trend towards increased food intake, however, these differences were not significant (B). Treatment with FGF19 or FGF21 significantly reduced adiposity at both doses tested again in a dose dependant manner (C), All FGF treatments caused a significant reduction in serum glucose in DIO animals, furthermore, the reduction in glucose observed with the two proteins was strikingly similar (D).</p

    Inhibition of FGF21 signaling also blocks FGF19 action in vitro.

    No full text
    <p><i>Panel 1.</i> In 3T3-L1/KLB fibroblasts co-treatment with the competitive agonist ΔN17 was able to block the induction of ERK phosphorylation caused not only by FGF21 but also by FGF19 (A). In our glucose uptake assay in 3T3-L1 adipocytes ΔN17 also suppressed the activity of both FGF19 (B) and FGF21 (C). <i>Panel 2.</i> To determine if the inhibition of FGF19/21 signaling we see in vitro translates to effects on metabolic parameters in vivo we examined fed and fasted glucose levels in ob/ob mice treated with FGF21, ΔN17 or a combination of both. In fed mice treatment with ΔN17 alone had no effect on serum glucose. FGF21 treatment reduced glucose levels significantly in the fed state, however, when the two treatments are combined the effect of FGF21 to reduce glucose is abolished (D). In fasted animals FGF21 again reduced glucose, an effect blocked by combination with ΔN17. Interestingly, we found that in fasted animals treatment with ΔN17 partially blocked the normal reduction in the serum glucose, suggesting ΔN17 may interfere in the regulation of glucose homeostasis (E).</p

    FGF19 treatment leads to hepatocellular proliferation.

    No full text
    <p>All mice received a constant infusion of BRDU during the 7 days of treatment. At the end of treatment samples of liver were harvested, preserved in formalin, processed routinely, and embedded in paraffin. Tissue sections were cut, immunolabeled for BRDU, and counterstained with hematoxylin. Representative sections are shown here from mice receiving injections of phosphate buffered saline (PBS; A), FGF19 (B), or FGF21 (C). The average number of BRDU-positive nuclei per 200× microscopic field is shown. Mice administered FGF19 had a statistically significant increase (* = p<0.0001) in the numbers of hepatocytes with BRDU-positive nuclei when compared to mice administered PBS (D). In contrast to FGF19, FGF21 did not induce hepatocellular proliferation. The arrowheads indicate the location of the centrilobular veins.</p

    The “hormone like” FGFs exhibit different signaling properties in vitro.

    No full text
    <p><i>Panel 1.</i> In 3T3-L1 fibroblasts over-expressing KL we saw phosphorylation of the FGF target ERK upon treatment with FGF23, while FGF19 and 21 had no effect (A). Conversely, in 3T3-L1/KLB cells we saw no effect of FGF23 but potent signaling with FGF19 or FGF21 treatment (B). When we examined glucose uptake in the 3T3-L1/KL cells we found that only FGF23 lead to its stimulation (C). As we saw with pERK in 3T3-L1/KLB cells FGF19 and FGF21 both increased glucose uptake significantly (D). In 3T3-L1 fibroblasts expressing FGFR4 in the absence of KLB only FGF19 was able to increase glucose uptake (E). Furthermore, in Hep3B cells which show a relative enrichment of FGFR4, FGF19 was significantly more potent than FGF21 in inducing expression of the immediate early gene EGR1 (F). When 3T3-L1 cells were differentiated to become mature adipocytes FGF19 was also more potent than FGF21 even in the absence of FGFR4 expression suggesting a possible unknown factor which is not present on fibroblasts may be affecting FGF19's action in these cells, or vice versa (G). In 3T3-L1 adipocytes treated with either FGF19, FGF21 or a combination of both we did not see any additive or synergistic effects of combination treatment over individual therapy suggesting FGF19 and FGF21 share a common mechanism of action (H). To confirm our initial results regarding the specificity of FGF19 for FGFR4 we turned to L6 cells which have been reported to have extremely low expression of FGFRs and KLs. In parental L6 cells treatment with FGF19 had no effect on the level of ERK phosphorylation, however, when cells were transfected with KLB a small but significant increase in pERK was detected. Furthermore, when FGFR4 was added the response to FGF19 stimulation was magnified. Interestingly, we saw again that in cells transfected with FGFR4 alone FGF19 was also able to induce pERK confirming KLB independent signaling with this ligand can occur (I). In contrast to FGF19, cells treated with FGF21 showed pERK induction only in the presence of KLB with the level of this baseline induction similar to that seen with FGF19 treatment (J).</p

    Expression of FGF receptors and Klotho co factors in cell culture models.

    No full text
    <p>In 3T3-L1 cells we found a high level of FGFR1 expression along with modest levels of FGFR2 and FGFR3. In these cells FGFR4, KL and KLB were not detectable (A). In Hep3B cells there was detectable expression of all 4 FGF receptor subtypes, however, we detected especially high levels of FGFR4. Hep3B cells were also found have appreciable expression of KLB while KL was not detectable (B). In L6 cells expression of all FGFRs was extremely low in comparison to other cells lines we screened in addition to undetectable levels of KLB at baseline (C).</p
    corecore